Free shipping on all orders over $ 500

LY335979

Cat. No. M1845

LY335979 Structure

Synonym: Zosuquidar trihydrochloride

Size Price Availability Quantity
5mg USD 120 In stock
10mg USD 150 In stock
25mg USD 240 In stock
50mg USD 360 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

LY335979 (Zosuquidar trihydrochloride) is a selective Pgp (P-glycoprotein) inhibitor with a Ki of 59 nM. LY335979 displays the following characteristics of an 'ideal modulator' of Pgp-mediated multidrug resistance: high affinity binding to Pgp, high potency for in vitro reversal of compound resistance, high therapeutic index (activity was demonstrated at doses ranging from 1-30 mg/kg) observed in in vivo antitumor efficacy experiments, and a lack of pharmacokinetic interactions that alter the plasma concentration of coadministered oncolytic agents. These desirable features strongly suggest that LY335979 is an exciting new clinical agent to test the hypothesis that inhibition of P-glycoprotein activity will result in reversal of multidrug resistance in human tumors. LY335979 was without significant effect on the pharmacokinetics of these anticancer agents.

Protocol
Cell Experiment
Cell lines MCF-7 and MCF-7/ADR cells
Preparation method Cytotoxicity Assays.
Cell viability was determined using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction method. Cells were harvested during logarithmic growth phase, and seeded in 96-well plates (Costar) at 7.5X104 cells/well. The cells were then cultured for 72 h in the presence of oncolytics with or without modulators. MCF-7 and MCF-7/ADR cells were incubated 24 h before the addition of the drug with and without the modulator. Modulators were prepared as 2 mM DMSO stocks and added to wells to give final concentrations ranging from 0.05 to 5 uM. After 72 h, 20 ul of freshly prepared 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (5 mg/mL in Dulbecco's PBS) was added to each well and incubated for 4 h in a 37°C incubator containing 5% CO2. Cells were pelleted in a Sorvall RT6000B centrifuge, 70 p.1of medium was carefully removed from each well, and 100ul of 2-propanol/0.04 N HC1 was added. Cells were resuspended 5-10 times with a Multipipettor or until no particulate matter was visible. Plates were immediately read on a Titertek Multiskan MCC/340 microplate reader Flow Laboratories (McLean, VA) with a test wavelength of 570 nm and a reference wavelength of 630 nm.Controls were measured in quadruplicate and modulators were measured in duplicate. Cytotoxicity analyses were also performed using the CeliTiter 96 AQueous assay kit (Promega Corp., Madison, WI) according to the manufacturer's instructions.
Concentrations 0.05~5µM
Incubation time 72h
Animal Experiment
Animal models P388/ADR tumors bearing mice
Formulation stock solution was 2.5 to 5 mg/nil in 5% manrntol
Dosages 20 mg/kg once daily for 5 days
Administration i.v. injection
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 637.00
Formula C32H31F2N3O2.3HCl
CAS Number 167465-36-3
Purity >99%
Solubility DMSO ≥120 mg/mL
Storage at -20°C
References

Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease et al. J Pharm Sci. 2012 May;101(5):1888-97. PMID: 22359351.

Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj et al. Breast Cancer Res Treat. 2012 Jul;134(1):117-29. PMID: 22228402.

Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux.
Fuchs et al. Eur J Pharm Sci. 2012 Apr 11;45(5):533-8. PMID: 22198311.

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.
Cripe et al. Blood. 2010 Nov 18;116(20):4077-85. PMID: 20716770.

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
Dantzig AH, et al. Cancer Res. 1996 Sep 15;56(18):4171-9. PMID: 8797588.

Related P-gp Products
Elacridar (GF120918)

Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

Polyoxyethylene stearate

Polyoxyethylene stearate (POES) is a non-ionic emulsifying agent.

Tariquidar

Tariquidar (XR9576) is a selective, highly efficacious third generation P-glycoprotein (P-gp) inhibitor.

Biricodar

The pipecolinate derivative Biricodar (VX-710, Incel) is a clinically applicable modulator of P-glycoprotein (Pgp) with potential chemosensitizing activity.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: LY335979, Zosuquidar trihydrochloride supplier, P-gp, inhibitors

Contact Us
  • Tel: +1-800-660-8580
  • Email: sales@abmole.com
  • Tel: +32 (0)2 738 09 61
  • Email: eu.order@abmole.com

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.